Argent Capital Management LLC boosted its stake in icad inc. (NASDAQ:ICAD) by 13.2% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 713,650 shares of the technology company’s stock after purchasing an additional 82,967 shares during the quarter. Argent Capital Management LLC owned about 4.30% of icad inc. worth $2,990,000 as of its most recent SEC filing.

Separately, Essex Investment Management Co. LLC increased its holdings in icad inc. by 822.3% in the second quarter. Essex Investment Management Co. LLC now owns 139,766 shares of the technology company’s stock valued at $586,000 after purchasing an additional 124,612 shares during the last quarter. 23.74% of the stock is owned by institutional investors and hedge funds.

A number of equities research analysts recently commented on the company. ValuEngine upgraded icad inc. from a “strong sell” rating to a “sell” rating in a report on Monday, October 2nd. Laidlaw reissued a “buy” rating and issued a $11.00 target price on shares of icad inc. in a research note on Tuesday, July 25th.

COPYRIGHT VIOLATION NOTICE: This news story was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another site, it was illegally stolen and reposted in violation of United States and international copyright laws. The legal version of this news story can be read at

icad inc. (NASDAQ ICAD) traded down 0.87% on Monday, reaching $4.55. The company’s stock had a trading volume of 3,631 shares. The stock’s market cap is $75.50 million. icad inc. has a 52-week low of $2.82 and a 52-week high of $6.07. The firm’s 50-day moving average price is $3.85 and its 200-day moving average price is $4.35.

icad inc. (NASDAQ:ICAD) last posted its quarterly earnings data on Tuesday, August 8th. The technology company reported ($0.16) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.19) by $0.03. icad inc. had a negative return on equity of 44.39% and a negative net margin of 34.74%. The firm had revenue of $6.41 million during the quarter, compared to analyst estimates of $6.41 million. On average, equities analysts expect that icad inc. will post ($0.54) earnings per share for the current year.

In other icad inc. news, Director Dr Lawrence Howard acquired 10,000 shares of the stock in a transaction dated Wednesday, August 23rd. The stock was purchased at an average cost of $3.33 per share, with a total value of $33,300.00. Following the transaction, the director now owns 488,022 shares in the company, valued at approximately $1,625,113.26. The acquisition was disclosed in a filing with the SEC, which is available at this link. Company insiders own 19.10% of the company’s stock.

icad inc. Profile

iCAD, Inc is a provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer. The Company provides image analysis and clinical decision support solutions for mammography, Magnetic Resonance Imaging and Computed Tomography imaging. It operates in two segments: Cancer Detection (Detection) and Cancer Therapy (Therapy).

Want to see what other hedge funds are holding ICAD? Visit to get the latest 13F filings and insider trades for icad inc. (NASDAQ:ICAD).

Institutional Ownership by Quarter for icad inc. (NASDAQ:ICAD)

Receive News & Stock Ratings for icad inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for icad inc. and related stocks with our FREE daily email newsletter.